6981 Murata Manufacturing Co. Ltd.

Murata announces the SCH16T-K01, a next generation 6DoF inertial sensor

The SCH16T-K01 is an inertial 6DoF XYZ-axis gyroscope and XYZ-axis accelerometer that enables high precision machine control and positioning applications. The device is the first launched product version from Murata's next generation SCH16T 6DoF family, which has further variants upcoming in the future.

This press release features multimedia. View the full release here:

[Murata Manufacturing Co., Ltd.] SCH16T-K01 (Photo: Business Wire)

[Murata Manufacturing Co., Ltd.] SCH16T-K01 (Photo: Business Wire)

Murata’s industry-proven 3D MEMS process has been updated and enhanced for the SCH16T product family. This sensor has been designed to meet the market need for better positioning solutions and delivers an unmatched level of performance, supported by several added time synchronization features.

The SCH16T-K01 includes a sophisticated gyro with typical bias instability of 0.5dph and up to 0.3mdps/√Hz noise density. The accelerometer has a dynamic range of up to 26g, which provides resistance against saturation and vibration. Overall, the component exhibits excellent linearity and offset stability through the whole temperature range.

The component’s output is also internally cross-axis compensated, eliminating the need for extensive calibration at the user’s end. In addition, through the integration of these features, the SCH16T-K01 can deliver incredibly accurate measurements in machine control and guidance without needing field calibrations.

The SCH16T-K01 is ideally suited to industrial applications and use cases such as construction and agricultural machines, material handling equipment, and marine instrumentation.

To find out more, visit .

Please contact us for details:

EN
09/01/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Murata Manufacturing Co. Ltd.

Pelham Smithers
  • Pelham Smithers

PSA Strategy: Japan Stock Market Quarterly for 2025 Q4

For almost three years the Nikkei 225 has been tracking its performance from the 2003~5 bull market, albeit at levels some 3.3x higher In this report, Pelham Smithers discusses the similarities and asks three key questions: (1) Can we continue to track 2005 through the rest of the year; (2) Whatever happens in Q4, should we fear or be hopeful for 2026? And (3) Who are the upcoming winners and losers.

Pelham Smithers
  • Pelham Smithers

PSA Technology: Japanese AI Stocks Revisited

At first glance, it feels like the Japanese stock market has reacted unusually slowly to the surge in AI infrastructure stocks in the US. Pelham Smithers flags winners on this theme.

 PRESS RELEASE

Murata annonce la production de « CELLNETTA », le premier filtre métal...

KYOTO, Japon--(BUSINESS WIRE)-- Murata Manufacturing Co., Ltd. (TOKYO : 6981) (ISIN : JP3914400001) a annoncé aujourd’hui avoir commercialisé et produit en masse avec succès « CELLNETTA », le premier*1 filtre métallique de fractionnement cellulaire au monde conçu pour la sélection et la récupération rapides et précises de cellules cibles à partir de suspensions cellulaires*2 utilisées en médecine régénérative et dans la recherche et le développement de produits pharmaceutiques cellulaires. Les applications visées comprennent le fractionnement (sélection et récupération), la concentration et la...

 PRESS RELEASE

Murata Announces Production of "CELLNETTA" – the World's First Metal C...

KYOTO, Japan--(BUSINESS WIRE)-- Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) announced today that has successfully commercialized and mass produced "CELLNETTA," the world’s first*1 metal cell fractionation filter designed for the rapid and precise selection and recovery of target cells from cell suspensions*2 used in regenerative medicine and cell pharmaceutical research and development. Target applications include fractionation (selection and recovery), concentration, and filtration in research and development for regenerative medicine technologies or cellular pharmaceuti...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch